Y
Yongzeng Wang
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 18
Citations - 4189
Yongzeng Wang is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 11, co-authored 16 publications receiving 3194 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila,Isabelle Riviere,Xiuyan Wang,Shirley Bartido,Jae H. Park,Kevin J. Curran,Stephen S. Chung,Jolanta Stefanski,Oriana Borquez-Ojeda,Malgorzata Olszewska,Jinrong Qu,Teresa Wasielewska,Qing He,Mitsu Fink,Himaly Shinglot,Maher Youssif,Mark Satter,Yongzeng Wang,James Hosey,Hilda Quintanilla,Elizabeth Halton,Yvette Bernal,Diana C. G. Bouhassira,Maria E. Arcila,Mithat Gonen,Gail J. Roboz,Peter Maslak,Dan Douer,Mark G. Frattini,Sergio Giralt,Michel Sadelain,Renier J. Brentjens +31 more
TL;DR: Diagnostic criteria for a severe cytokine release syndrome (sCRS) is defined and serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS.
Journal ArticleDOI
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park,Isabelle Riviere,Mithat Gonen,Xiuyan Wang,Brigitte Senechal,Kevin J. Curran,Craig S. Sauter,Yongzeng Wang,Bianca Santomasso,Elena Mead,Mikhail Roshal,Peter Maslak,Marco L. Davila,Renier J. Brentjens,Michel Sadelain +14 more
TL;DR: A phase 1 trial involving adults with relapsed B‐cell ALL who received an infusion of autologous T cells expressing the 19‐28z CAR at the Memorial Sloan Kettering Cancer Center found that patients with a low disease burden before treatment had markedly enhanced remission duration and survival and had a markedly lower incidence of the cytokine release syndrome and neurotoxic events after infusion.
Journal ArticleDOI
Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01.
Jinghua Piao,Susan Zabierowski,Brittany N. Dubose,Ellen J. Hill,Monalisa Navare,Nidia L Claros,Siera Rosen,Kiran Ramnarine,Callie Horn,Craig Fredrickson,Wong Karen,Brent Safford,Sonja Kriks,Abderrahman El Maarouf,Urs Rutishauser,Claire Henchcliffe,Yongzeng Wang,Isabelle Riviere,Shannon Mann,Vladimir P. Bermudez,Stefan Irion,Lorenz Studer,Mark J. Tomishima,Viviane Tabar +23 more
TL;DR: In this paper, the midbrain dopamine neuron grafts from human embryonic stem cells and manufactured large-scale cryopreserved dopamine progenitors for clinical use were used for Parkinson's disease.
Journal ArticleDOI
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Mark B. Geyer,Isabelle Riviere,Brigitte Senechal,Xiuyan Wang,Yongzeng Wang,Terence J. Purdon,Meier Hsu,Sean M. Devlin,M. Lia Palomba,Elizabeth Halton,Yvette Bernal,Dayenne G. van Leeuwen,Michel Sadelain,Jae H. Park,Renier J. Brentjens +14 more
TL;DR: Conditioning chemotherapy and 19-28z CAR T-cells were acceptably tolerated across investigated dose levels in heavily pretreated patients with R/R CLL and indolent B-NHL, and a subgroup of patients achieved durable CR.
Journal ArticleDOI
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
Mark B. Geyer,Isabelle Riviere,Brigitte Senechal,Xiuyan Wang,Yongzeng Wang,Terence J. Purdon,Meier Hsu,Sean M. Devlin,Elizabeth Halton,Nicole Lamanna,Jürgen Rademaker,Michel Sadelain,Renier J. Brentjens,Jae H. Park +13 more
TL;DR: The use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab was reported.